doi: 10.1161/ATVBAHA.107.160192
© 2008 American Heart Association, Inc.
Brief Review |
Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome
From the Sahlgrenska Center for Cardiovascular and Metabolism Research, Wallenberg Laboratory for Cardiovascular Research and the Department of Molecular and Clinical Medicine (M.A., S.-O.O., J.B.), The Sahlgrenska Academy at University of Gothenburg, Sweden; and the Division of Diabetes (M.-R.T.), University of Helsinki, Finland.
Correspondence to Martin Adiels Wallenberg Laboratory Sahlgrenska University Hospital 41345 Gothenburg, Sweden. E-mail Martin.adiels{at}wlab.gu.se
Series Editor: Marja-Riitta Taskinen
Metabolic Syndrome and Atherosclerosis
ATVB In Focus
Preview Brief Reviews in this Series:
•Grundy, SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28:629–636.
•Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:39–46.
•Kotronen A, Yki-Järvinen. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27–38.
•Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2276–2283.
•Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-, PPAR-
, and LXRs in mice and men. Arterioscler Thromb Vasc Biol. 2008;28:1050–1059.
•Kockx M, Jessup W, Kritharides L. Regulation of endogenous apolipoprotein E secretion by macrophages. Arterioscler Thromb Vasc Biol. 2008;28:1060–1067.
 |
Abstract |
|---|
 Top Abstract IntroductionFormation and Metabolism of...Dyslipidemia in Insulin...Regulators of VLDL AssemblyWhich Factors Predict...Does Liver Fat Cause...Sources of Fatty Acids...Lipid Management of DyslipidemiaConclusionReferences |
|---|
Insulin resistance is a key feature of the metabolic syndrome and often progresses to type 2 diabetes. Both insulin resistance and type 2 diabetes are characterized by dyslipidemia, which is an important and common risk factor for cardiovascular disease. Diabetic dyslipidemia is a cluster of potentially atherogenic lipid and lipoprotein abnormalities that are metabolically interrelated. Recent evidence suggests that a fundamental defect is an overproduction of large very low–density lipoprotein (VLDL) particles, which initiates a sequence of lipoprotein changes, resulting in higher levels of remnant particles, smaller LDL, and lower levels of high-density liporotein (HDL) cholesterol. These atherogenic lipid abnormalities precede the diagnosis of type 2 diabetes by several years, and it is thus important to elucidate the mechanisms involved in the overproduction of large VLDL particles. Here, we review the pathophysiology of VLDL biosynthesis and metabolism in the metabolic syndrome. We also review recent research investigating the relation between hepatic accumulation of lipids and insulin resistance, and sources of fatty acids for liver fat and VLDL biosynthesis. Finally, we briefly discuss current treatments for lipid management of dyslipidemia and potential future therapeutic targets.
Diabetic dyslipidemia is a cluster of potentially atherogenic lipid and lipoprotein abnormalities that are metabolically interrelated. Recent evidence suggests that a fundamental defect is an overproduction of large very low–density lipoprotein (VLDL) particles. Here, we review the pathophysiology of VLDL biosynthesis and metabolism in the metabolic syndrome.
Key Words: apolipoprotein B • VLDL1 • insulin resistance • metabolic syndrome • nonalcoholic fatty liver disease • stable isotopes • kinetics
|
Introduction |
|---|
|
TopAbstractIntroductionFormation and Metabolism of...Dyslipidemia in Insulin...Regulators of VLDL AssemblyWhich Factors Predict...Does Liver Fat Cause...Sources of Fatty Acids...Lipid Management of DyslipidemiaConclusionReferences |
|---|
Insulin resistance is a key feature of the metabolic syndrome and can lead to the development of type 2 diabetes.1,2 These conditions are today increasingly common, primarily because of the increased prevalence of a sedentary lifestyle and obesity.3 Insulin resistance and type 2 diabetes are characterized by dyslipidemia, which is a major risk factor for cardiovascular disease (CVD). This dyslipidemia is characterized by the so-called lipid triad4—high levels of plasma triglycerides, low levels of high-density lipoprotein (HDL) cholesterol, and the appearance of small, dense, low-density lipoproteins (sdLDL)—and excessive postprandial lipemia.1,2,5–7 Diabetic dyslipidemia frequently precedes type 2 diabetes by several years, indicating that the disturbance of lipid metabolism is an early event in the development of cardiovascular complications of type 2 diabetes.1,2 Indeed, patients with insulin resistance both with and without type 2 diabetes display qualitatively similar lipid abnormalities.2
It is now recognized that the different components of diabetic dyslipidemia are not isolated abnormalities but are closely linked to each other metabolically,1,2,5 and are mainly initiated by the hepatic overproduction of large triglyceride-rich very low–density lipoproteins (VLDL1).1,5 It is thus of key importance to elucidate the mechanisms involved in the overproduction of VLDL1 in diabetic dyslipidemia. Here, we review the pathophysiology of VLDL metabolism in the metabolic syndrome and discuss how increased liver fat induces overproduction of VLDL1.
|
Formation and Metabolism of VLDL |
|---|
|
TopAbstractIntroductionFormation and Metabolism of...Dyslipidemia in Insulin...Regulators of VLDL AssemblyWhich Factors Predict...Does Liver Fat Cause...Sources of Fatty Acids...Lipid Management of DyslipidemiaConclusionReferences |
|---|
Production of Triglyceride-Poor VLDL in the Liver
The assembly of VLDL involves a stepwise lipidation of the structural protein apolipoprotein B100 (apoB100) in the liver (Figure 1).8,9 The initiating step is lipidation of apoB by microsomal triglyceride transfer protein (MTP) in the rough endoplasmic reticulum.10,11 This results in the formation of a primordial pre-VLDL lipoprotein particle,12 which is converted to a triglyceride-poor VLDL particle by additional lipidation.13
|
Maturation of VLDL in the Liver
The triglyceride-poor VLDL particle can either be secreted from the cell as VLDL2 or further lipidated to form a mature, triglyceride-rich VLDL (ie, VLDL1).13,14 The lipidation is dependent on the small GTP-binding protein ADP-ribosylation factor 1 (ARF-1).15 This protein plays a central role in membrane trafficking between the ER and the Golgi apparatus, which is consistent with recent results showing that the late steps of VLDL formation occur in the Golgi apparatus.14,16–18 However, there are data to suggest that the ER is the site of maturation.19 The conversion of triglyceride-poor to triglyceride-rich VLDL requires a bulk addition of triglycerides and thus differs from the stepwise lipidation of apoB to form pre-VLDL.13 VLDL formation is highly dependent on the accumulation of triglycerides in the cytosol, and several authors have demonstrated that the fatty acids used for the biosynthesis of VLDL-triglycerides are derived from triglycerides stored in cytosolic lipid droplets.20–22
Delipidation of VLDL
VLDL, intermediate-density lipoprotein (IDL), and LDL all contain 1 apoB100 per particle and are linked in a delipidation cascade. Triglyceride-rich VLDL is released from the liver and converted to IDL by lipoprotein lipase (LPL)-catalyzed hydrolyzation of the lipids. LPL can be inhibited by apoCIII.23 IDL can be further hydrolyzed by hepatic lipase to cholesterol-rich LDL, which is catabolized mainly by hepatic uptake of LDL through LDL receptors.24 Results from kinetic studies suggest that the liver also secretes smaller particles such as IDL and LDL25,26 and that IDL can be catabolized though LDL receptor-mediated uptake.27,28 During these processes, apoB100 remains with the particle.
|
Dyslipidemia in Insulin Resistance and Type 2 Diabetes |
|---|
|
TopAbstractIntroductionFormation and Metabolism of...Dyslipidemia in Insulin...Regulators of VLDL AssemblyWhich Factors Predict...Does Liver Fat Cause...Sources of Fatty Acids...Lipid Management of DyslipidemiaConclusionReferences |
|---|
Abnormal concentrations of lipids and apolipoproteins can result from changes in the production, conversion, or catabolism of lipoprotein particles. Thus, although static measurements are important, they do not reveal the underlying mechanisms involved in the dysregulation of lipid disorders. To infer this information, it is necessary to perform in vivo tracer/tracee studies in which the rates of synthesis or catabolism of a particular lipoprotein or apolipoprotein can be determined.
Kinetic Studies
Today, the majority of in vivo lipoprotein kinetic studies are performed using infusion of stable isotopes. The metabolism of lipoprotein particles can be followed by injecting amino acids labeled with stable isotopes that are then incorporated into proteins such as apoB100.29 The triglyceride content can be followed by infusion of labeled glycerol or free fatty acids.30 Several multicompartmental models have been proposed over the years to provide estimates of protein secretion and catabolism,31 and have been designed to analyze either the VLDL-apoB32,33 or the VLDL-triglycerides.34,35 Indeed, in recent years, much has been learned about the metabolic changes that contribute to dyslipidemia (Figure 2). To enhance the understanding of the pathways leading to VLDL subpopulations, we developed a combined multicompartmental model that allows the kinetics of triglyceride and apoB100 in VLDL1 and VLDL2 to be simultaneously assessed (Figure 3).36 Previous models combined infusion of [3H]glycerol and VLDL exogenously labeled with iodine,37–40 or assessed the apoB and triglyceride kinetics independently.41
|
|
Increased Levels of VLDL
The dyslipidemia seen in insulin resistance and type 2 diabetes is associated with excess hepatic production of VLDL.42–45 We have observed that this increase is in the VLDL1 fraction.46,47 By contrast, hepatic secretion of VLDL2 is comparable in insulin-resistant and insulin-sensitive subjects.5,46,48,49 In subjects with type 2 diabetes, hepatic uptake of VLDL, IDL, and LDL is decreased, resulting in increased plasma residence time of these lipoproteins,50–52 which further contributes to the increased accumulation. There are also reports of increased production of IDL and LDL in insulin-resistant women without diabetes,53 and in men with mild but not severe diabetes.54
Formation of sdLDL
The formation of sdLDL is closely associated with insulin resistance and hypertriglyceridemia,6 and the VLDL1-triglyceride level is the major predictor of LDL size in individuals with or without type 2 diabetes.1,7,49,55 The mechanism that leads to the formation of sdLDL is well elaborated, and both cholesteryl ester transfer protein (CETP) and hepatic lipase are involved: (1) CETP facilitates the transfer of triglycerides from VLDL1 to LDL; (2) the resulting triglyceride-rich LDL is a preferred substrate for hepatic lipase; and (3) increased lipolysis of triglyceride-rich LDL results in the formation of sdLDL.1,6 Thus, it seems that the presence of large triglyceride-rich VLDL1 particles is a prerequisite for sdLDL formation, and such correlations have been observed.7,49,55 However, sdLDL are also observed in patients with type 2 diabetes and insulin resistance with close to normal triglyceride levels.56 This might be explained by increased hepatic lipase activity.
Several studies have shown that the presence of sdLDL particles is associated with increased cardiovascular risk.57–60 However, it is still under debate whether sdLDL levels add independent information on risk assessment over standard risk factors.61
Decreased Levels of HDL
Increased levels of VLDL1 also alter the composition of HDL through the actions of CETP and hepatic lipase, leading to the formation of small dense HDL and increased catabolism of these particles.62 Thus, there is an inverse correlation between HDL and liver fat.49
Postprandial Lipemia
Intestinal-derived apoB48-containing chylomicrons contribute to the large triglyceride-rich lipoproteins in the postprandial state. Although approximately 80% of the increase in triglycerides after a fat load meal comes from apoB48-containing lipoproteins,63 approximately 80% of the increase in particle count is from apoB100.64,65 Moreover, the area under the curve (AUC) for apoB100 is 10-fold higher than that of apoB48,66 and the production rate of apoB100 is 15 to 20 times higher than that of apoB48.67,68 ApoB48 and apoB100-containing particles are cleared from the circulation by a common pathway and therefore compete for clearance.69 Thus, the major contribution to an atherogenic lipoprotein profile from chylomicrons is likely their interference with apoB100 catabolism.
The Lipid Triad
Collectively, the key components of the diabetic dyslipidemia can be attributed to increased accumulation of VLDL particles, predominantly caused by overproduction of VLDL1. A similar dyslipidemia is also present in other syndromes, such as familial combined hyperlipidemia,70 hyperapobetalipoproteinemia,71 familial dyslipidemic hypertension,72 LDL subclass pattern B,73 and the Reaven syndrome,74 which are all characterized by increased hepatic apoB overproduction and insulin resistance.
|
Regulators of VLDL Assembly |
|---|
|
TopAbstractIntroductionFormation and Metabolism of...Dyslipidemia in Insulin...Regulators of VLDL AssemblyWhich Factors Predict...Does Liver Fat Cause...Sources of Fatty Acids...Lipid Management of DyslipidemiaConclusionReferences |
|---|
Fatty Acids Increase VLDL Formation
An increased delivery of fatty acids increases the secretion of VLDL-triglycerides and apoB100 from human liver and from hepatocytes and HepG2 cells.75,76 Our turnover studies in vivo have demonstrated the importance of hepatic triglycerides for the assembly and secretion of VLDL.49 These studies have also confirmed the stepwise lipidation of VLDL1 and demonstrated that the secretion of VLDL1-apoB100 increases with increasing concentrations of liver lipids.5,49 Importantly, the relationship between triglyceride and apoB production rates for VLDL1 showed that subjects with type 2 diabetes secrete more—not larger—VLDL1 particles than nondiabetic controls.5,36,49 Thus, the amount of lipid added to an individual VLDL2 particle to produce VLDL1 is equal in subjects with type 2 diabetes and nondiabetic controls, but the rate of conversion is increased in subjects with type 2 diabetes.
Insulin Shifts the Balance From VLDL1 to VLDL2
Only a few studies have investigated the acute effect of insulin on VLDL kinetics in humans in vivo.75,77–80 Although the modeling approaches differ, they all show decreased secretion of VLDL-triglycerides and VLDL-apoB. Furthermore, insulin infusion has a greater effect on the secretion of VLDL-triglycerides than VLDL-apoB,75,78,79 and it has been shown to suppress mainly VLDL1-apoB production, with little effect on VLDL2-apoB100 production.77,80 Thus, insulin not only reduces the number of overall VLDL particles, but also shifts the balance between VLDL2 and VLDL1 to reduce the relative proportion of VLDL1 particles. However, the acute effect of insulin on lipolysis of circulating lipoproteins still remains to be fully elucidated.
Insulin has been shown to decrease VLDL formation by at least 2 mechanisms: (1) by regulating the amount of fatty acids in the circulation79; and (2) by direct suppression of the production of VLDL1 in the liver, independent of the availability of fatty acids.78 The molecular mechanisms involved in the direct suppression of VLDL1 are elusive, and several mechanisms have been proposed. Sparks and coworkers have shown that activation of phosphatidylinositol 3-kinase (PI3-K) is necessary for the insulin-stimulated decrease in apoB secretion from rat hepatocytes.81–83 In addition, insulin downregulates MTP expression via activation of the mitogen-activated protein kinase (MAPK) pathway.84,85 Insulin may also decrease VLDL secretion by inhibiting the activity of the transcription factor Foxa2.86 Recent studies in ob/ob mice have shown that Foxa2 and its coactivator peroxisome proliferator-activated receptor gamma (PPAR) coactivator β (Pgc-1β) promote fatty acid oxidation and stimulation of MTP in livers, resulting in increased VLDL secretion.87,88 However, these results require further investigation as it is surprising to observe the combination of increased fatty acid oxidation and VLDL secretion.
PPAR Agonists Decrease VLDL-Triglyceride Secretion
Fibrates activate PPAR, which plays a key role in the regulation of energy homeostasis and inflammation.89 Fibrates have been used since the 1970s for their lipid-modifying properties, which include reducing plasma triglycerides and VLDL and increasing HDL cholesterol.89
Experiments in rat liver cells have shown that the triglyceride-lowering effect of fibrates is partly explained by increased oxidation of free fatty acids,90 diverting them away from triglyceride synthesis and thus reducing the hepatic synthesis of triglyceride-rich lipoproteins.91,92 However, in humans, data on direct effects of fibrates on VLDL production rate are inconclusive. The effect on lowering plasma triglycerides seems to be caused by an increased clearance rate,52,93,94 which is supported by the observations that PPAR induces expression of LPL95 and inhibits the synthesis of apoCIII.96
Brain Glucose Controls VLDL Secretion
Rossetti and coworkers have recently shown that hypothalamic glucose-sensing mechanisms regulate liver, but not intestinal, VLDL-triglyceride production, and that this regulation is lost in diet-induced obesity.97,98 The cross-talk between the brain and the liver couples carbohydrate sensing to lipoprotein secretion by curtailing the activity of stearoyl-coenzyme A (CoA) desaturase-1 (SCD1) in the liver and by interfering with a late step in the hepatic assembly and secretion of VLDL particles. These findings are consistent with a homeostatic loop in which the increased availability of carbohydrates limits the endogenous output of lipids into the circulation. This mechanism would, together with insulin, acutely downregulate VLDL secretion after a meal. Glucose-induced hyperglycemia-hyperinsulinemia lowers VLDL-triglyceride secretion by 50%,99 but the effects of insulin and glucose cannot be separated from each other.
Further Evidence for Independent Regulation of VLDL1 and VLDL2
In addition to independent regulation of VLDL1 and VLDL2 production by insulin and PPAR agonists (as described above), there is evidence to indicate a primary effect of ethanol on the stimulation of production of VLDL1 particles in humans.100 In addition, endogenous cholesterol synthesis correlates with VLDL2-apoB but not VLDL1-apoB production.101 This finding provides further support for independent regulation of VLDL1 and VLDL2, and may explain why VLDL2 but not VLDL1 is increased in patients with increased plasma cholesterol, as in moderate hypercholesterolemia26 and familial hypercholesterolemia.28
|
Which Factors Predict Overproduction of VLDL1? |
|---|
|
TopAbstractIntroductionFormation and Metabolism of...Dyslipidemia in Insulin...Regulators of VLDL AssemblyWhich Factors Predict...Does Liver Fat Cause...Sources of Fatty Acids...Lipid Management of DyslipidemiaConclusionReferences |
|---|
We recently analyzed which features of type 2 diabetes and insulin resistance correlate with VLDL1 production, and revealed strong correlations with plasma glucose that are not apparent in the normal range of plasma glucose.46 By extending our study to monitor liver fat, intra-abdominal fat, subcutaneous fat, and adiponectin, we showed that fasting insulin, plasma glucose, intra-abdominal fat, and liver fat and HOMA-IR are predictors of VLDL1-apoB and VLDL1-triglyceride production.49 However, in a multiple regression analysis, only liver fat and plasma glucose remain significant.49 Moreover, the key predictors of liver fat are intraabdominal fat, adiponectin, and plasma glucose.49
Liver Fat Correlates with Reduced Effect of Insulin
Nonalcoholic fatty liver disease (NAFLD) is defined as fat accumulation in the liver that exceeds 5% to 10% of liver weight in individuals who do not consume significant amounts of alcohol.102 Recent data show that NAFLD strongly associates with type 2 diabetes, obesity, and hyperlipidemia.103–110
We tested the relationship between liver fat and VLDL1 suppression in subjects with a broad range of liver fat content.80 This study confirmed that liver fat predicts baseline VLDL1 production,49 and it also showed that liver fat is associated with lack of VLDL1 suppression in response to insulin: insulin downregulates VLDL1 secretion in subjects with low liver fat but fails to suppress VLDL1 secretion in subjects with high liver fat, resulting in overproduction of VLDL1.80 The reason for this lack of effect is not known. Insulin suppresses the nonesterified fatty acid (NEFA) pool to a similar extent regardless of liver fat level,80 and thus the high VLDL1 production in individuals with high liver fat must be facilitated either by using a greater portion of systemic NEFA or recruiting other sources of triglycerides, such as from hepatic stores.
|
Does Liver Fat Cause Insulin Resistance? |
|---|
|
TopAbstractIntroductionFormation and Metabolism of...Dyslipidemia in Insulin...Regulators of VLDL AssemblyWhich Factors Predict...Does Liver Fat Cause...Sources of Fatty Acids...Lipid Management of DyslipidemiaConclusionReferences |
|---|
Is the observed association between high liver fat and reduced suppression of VLDL1 by insulin the result of fatty liver, or is fatty liver merely a consequence of hepatic insulin resistance? The existence of a causal relationship between liver fat and hepatic insulin resistance is controversial with conflicting results: (1) Fatty liver and insulin resistance may be separate manifestations of metabolic derangements, and hepatic insulin resistance may reflect inflammation rather than lipid accumulation in this tissue.111 (2) Some studies suggest that insulin resistance is an essential requirement for the accumulation of hepatocellular fat.107,112,113 It is indeed possible that hepatic steatosis results from insulin resistance because the insulin signaling pathways that drive fatty acid biosynthesis in the liver are relatively sensitive to the high levels of portal insulin flux to the liver that accompany systemic insulin resistance. (3) Several lipid intermediates (eg, ceramides, GM3 ganglioside, and diacylglycerol) appear capable of inactivating components of the insulin signaling pathway.114,115 The levels of such metabolites are elevated in individuals with insulin resistance,116,117 and it is also likely that yet to be identified lipids or lipid-derived metabolites affect insulin sensitivity. However, the existence of a causative association between accumulation of specific lipid species and insulin resistance remains controversial.
Hepatic Insulin Resistance Induces Dyslipidemia Without Fatty Liver
Liver insulin receptor knockout (LIRKO) mice develop hyperinsulinemia but their livers do not respond to it, and thus they can be used to investigate the effects of pure hepatic insulin resistance.118 These mice develop a proatherogenic lipid profile (low HDL cholesterol and VLDL particles enriched in cholesterol) but not fatty liver.118 Normally, insulin promotes apoB degradation,82 but the insulin-resistant LIRKO mice over secrete apoB100.118 In contrast to insulin-resistant humans who over secrete both apoB and triglycerides as VLDL,29 LIRKO mice secrete less VLDL-triglyceride than control mice.118 This is probably attributable to low expression of SREBP-1c and SREBP-2 and their targets, and suggests that apoB is secreted as denser particles in LIRKO mice. These data suggest that pure insulin resistance drives changes in cholesterol homeostasis whereas other factors, such as hyperinsulinemia, drive increased production of triglycerides and the development of fatty liver. The significance of these results for humans with the metabolic syndrome remains to be determined.
Models of Fatty Liver With and Without Insulin Resistance
Shulman and coworkers have presented data supporting the hypothesis that hepatic steatosis leads to hepatic insulin resistance (see review119). In a rat model of NAFLD, lipid accumulation stimulates gluconeogenesis and activates protein kinase C epsilon (PKC-
) and c-Jun N-terminal kinase-1 (JNK1), which may interfere with tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and IRS-2 and impair the activation of glycogen synthase by insulin.120 Furthermore, recent data from this rat model show that antisense oligonucleotide (ASO)-mediated inhibition of PKC- reverses hepatic insulin resistance.121 PKC- has also been shown to be activated in the liver in patients with type 2 diabetes.122
Further work in transgenic animals has also directly tested and confirmed the hypothesis that hepatic steatosis can lead to insulin resistance: (1) Overexpression of glyceraldehyde-3-phosphate acyl transferase (GPAT) in rat liver results in major accumulation of triglycerides and in insulin resistance.123 (2) Expression of LPL in mouse liver causes hepatic steatosis and hepatic insulin resistance as manifested by increased hepatic glucose output.124 (3) Expression of malonyl-CoA decarboxylase in liver of rats with diet-induced insulin resistance resolves hepatic steatosis and improves whole-animal, liver, and muscle insulin sensitivities.125
Choi et al showed that ASO-mediated inactivation of acyl CoA diacylglycerol acyltransferase 2 (DGAT2) reverses diet-induced hepatic steatosis and insulin resistance by lowering hepatic diacylglycerol content and PKC- activation.126 However, Yu et al showed that ASO-mediated inhibition of DGAT2 reduces liver triglyceride content but does not improve insulin or glucose tolerance in mice fed a high-fat diet.127 Futhermore, Monetti et al showed that DGAT2-mediated lipid accumulation in the liver does not cause insulin resistance, indicating that hepatic steatosis can occur independently of insulin resistance.128 It is known that hepatic fat does not always associate with insulin resistance in humans: for example, liver steatosis without hepatic insulin resistance is observed in patients with familial heterozygous hypobetalipoproteinemia.129
How Could Storage of Neutral Lipid Droplets Cause Insulin Resistance?
The storage of lipids in mammalian cells was long considered to be a relatively simple process in which excess fatty acids are converted to neutral lipids and deposited in cytoplasmic lipid droplets. In recent years, the cell biology of the lipid droplet has begun to be understood in more detail.130 Accumulation of lipids in cells is a balance between the formation of lipid droplets and the hydrolysis of lipids in these droplets, catalyzed by hormone-sensitive lipase (HSL)131 and adipose triglyceride lipase (ATGL),132–134 and seems to be regulated by droplet-associated PAT proteins.135–137 Combined knockdown of the PAT proteins adipose differentiation-related protein (ADRP) and tail interacting protein of 47 kDa (TiP47) in cultured liver cells results in large lipid droplets with high turnover of triglycerides and insulin resistance.138 These data support an important structural role for ADRP and TiP47 as surfactant proteins at the surface of the lipid droplet, packaging lipid in smaller units, protecting lipid droplets against endogenous lipases, and facilitating triglyceride formation. Furthermore, by promoting lipid packaging into lipid droplets, the proteins may protect against the development of insulin resistance in hepatic cells.
A number of other enzymes and signaling proteins have also been shown to be associated with lipid droplets, and include fatty acid metabolic enzymes, eicosanoid-forming enzymes, specific kinases, and small GTPases.139–146 Thus, lipid droplets may integrate lipid metabolism, inflammatory mediator production, membrane trafficking, and intracellular signaling,130,147 consistent with the hypothesis that a disturbed interplay between these pathways may link liver fat and insulin resistance. However, the mechanisms involved remain to be elucidated. Recent studies identifying the SNARE protein SNAP23 as a molecular link between lipid droplets and insulin resistance in muscle cells support the hypothesis that it is not lipid droplets per se that promote the development of insulin resistance but other molecular mechanisms.148
|
Sources of Fatty Acids for Liver Fat and VLDL-Triglycerides |
|---|
|
TopAbstractIntroductionFormation and Metabolism of...Dyslipidemia in Insulin...Regulators of VLDL AssemblyWhich Factors Predict...Does Liver Fat Cause...Sources of Fatty Acids...Lipid Management of DyslipidemiaConclusionReferences |
|---|
Potential sources of fatty acids for liver fat and VLDL-triglycerides include: (1) peripheral fats stored in adipose tissue that flow to the liver via the plasma NEFA pool; (2) fatty acids synthesized within the liver through de novo lipogenesis (DNL); (3) dietary fatty acids that are transported via chylomicrons from the intestine to the NEFA pool and then to the liver; and (4) uptake of chylomicron remnants by the liver (Figure 4).149,150
|
Parks and coworkers have recently developed methodology to determine the fate of dietary fatty acids during the postprandial state and combined this technique with liver biopsy to simultaneously measure all 4 pathways of fatty acid delivery to the liver in patients suspected of having NAFLD.151 These quantitative metabolic data demonstrate that both elevated peripheral fatty acid flux and DNL contribute to liver fat and lipoprotein-triglycerides in NAFLD. Furthermore, a significant similarity was observed between the contributions of fatty acid sources for the liver triglyceride pools and the VLDL-triglyceride pool.
NEFA Pool
The hepatic uptake of fatty acids is not regulated and, as a result, the plasma NEFA concentration is directly related to the influx of fatty acids to the liver.152 Adipose tissue contributes approximately 80% of fatty acid content to the plasma NEFA pool in the fasted state, and even in the fed state it contributes approximately 60%.152 Thus, the most likely explanation for excess triglyceride accumulation in NAFLD is increased release of fatty acids from adipose tissue, which flow to the liver via the NEFA pool.149–151,153–155 In insulin-resistant states, insulin fails to suppress the activity of HSL and results in enhanced lipolysis and flux of fatty acids to the plasma NEFA pool.156
Visceral adiposity has been identified as an independent risk factor for cardiovascular disease and the metabolic syndrome, and the severity of NAFLD has been shown to be positively related to the visceral fat accumulation regardless of body mass index.157 We found that the insulin-induced suppression of NEFA was inversely related to intraabdominal fat volume but not to subcutaneous fat,80 which supports the important role of visceral fat as a source of NEFA flux to the liver.158,159 Indeed, the contribution of visceral adipose tissue lipolysis to NEFA increases as a function of visceral fat.159 However, even in viscerally obese people, 50% to 60% of NEFA entering the liver is from the systemic circulation.159
De Novo Lipogenesis
In fasting healthy human subjects, DNL in the liver contributes less than 5% to VLDL-triglyceride content.150 By contrast, DNL has been shown to account for approximately 25% of liver and VLDL-triglyceride content in hyperinsulinemic subjects with NAFLD.151 In healthy subjects, DNL is elevated after meals,160 which can be accounted for by elevations in the circulating levels of lipogenesis precursors. However, in NAFLD, DNL is already elevated in the fasted state, and further postprandial elevation is not observed.151 Indeed, constant elevation of DNL was also observed in control subjects fed a diet high in simple carbohydrates for 25 days.161 A recent study showed that insulin-resistant lean subjects produce 60% less glycogen than insulin-sensitive lean subjects after receiving 2 high-carbohydrate meals.162 The energy is diverted to increased hepatic DNL and results in increased plasma triglyceride and reduced HDL cholesterol levels.162 These observations reflect the sustained elevation of factors involved in hepatic DNL,150,151 such as SREBP1-c,163,164 the carbohydrate response element-binding protein (ChREBP),165 and PPAR.166–168
Chylomicron Synthesis and Other Sources
After entering the blood stream through chylomicron synthesis in the intestine, dietary fatty acids can be taken up by liver as chylomicron remnants.150 Alternatively, LPL catalyzes the release of fatty acids from the chylomicrons at a rate that exceeds tissue uptake, resulting in spill over of these fatty acids into the plasma NEFA pool.150
The contribution of dietary fatty acids to liver triglycerides depends on the fat content of the diet. Patients with NAFLD often consume significantly more saturated fats compared with control subjects matched for age, sex, and body mass index (BMI).169 However, studies of patients with NAFLD who had consumed a standardized 30% fat diet for the preceding 4 days showed that only 15% of the liver triglycerides were derived from dietary fatty acids.151
During the same 4-day study, the source of 10% to 20% of VLDL-triglycerides was not accounted for by 1 of the 4 recognized pathways.151 The source of these fatty acids has been proposed to be either hepatic storage or visceral fat that is transported to the liver through the portal vein.151 Indeed, liver biopsies in these subjects showed that only 38% of liver triglycerides could be accounted for by the recognized pathways during the 4-day study period.151 The estimated turnover rate of liver fat in these subjects was 38 days,151 compared with estimates of 1 to 2 days in normal individuals.170 Interestingly, Vedala et al have presented kinetic evidence for a significant contribution from a slow-turnover hepatic cytosolic triglyceride storage pool to fasting VLDG-triglycerides.171 The turnover time for this pool was longer in hypertriglyceridemic (HPTG) subjects with diabetes compared with nondiabetic subjects with and without HPTG, and it is likely that the contribution of the slow-turnover hepatic cytosolic triglyceride storage pool can explain the lack of accountability of liver triglycerides in NAFLD subjects.151
|
Lipid Management of Dyslipidemia |
|---|
|
TopAbstractIntroductionFormation and Metabolism of...Dyslipidemia in Insulin...Regulators of VLDL AssemblyWhich Factors Predict...Does Liver Fat Cause...Sources of Fatty Acids...Lipid Management of DyslipidemiaConclusionReferences |
|---|
Compared with nondiabetic individuals, patients with type 2 diabetes are at a much greater risk for CVD. Consequently, the treatment of CVD risk factors is a healthcare priority in this patient population. A number of clinical trials with 3-hydroxy-3-methylglutaryl (HMG) CoA (HMG-CoA) reductase inhibitors (statins) have shown significant CVD risk reduction through LDL cholesterol lowering in patients with diabetes,172–177 mainly through increased LDL-receptor activity.178 Increased LDL-receptor activity may also correct chylomicron metabolism.179 Indeed, the recently published Collaborative Atorvastatin Diabetes Study (CARDS), a placebo-controlled trial of patients with type 2 diabetes, was terminated 2 years earlier than its anticipated length owing to the significant reduction in number of CVD events observed in patients randomized to receive low-dose atorvastatin versus placebo.172 The statin therapy in this trial resulted in significant reduction of CVD events in patients with type 2 diabetes without previous CVD or high levels of LDL cholesterol and indicated that patients with type 2 diabetes may be candidates for statin therapy regardless of LDL cholesterol level or absence of a previous CV event. Thus, statins are safe and efficacious in reducing CVD events in patients with type 2 diabetes, but recent clinical trials have demonstrated that statins fail to completely reverse the increased risk of CVD in subjects with type 2 diabetes.172,173
Fibrates are associated with positive lipid-modifying properties (discussed earlier), and it was anticipated that fibrates would significantly reduce CVD risk in high-risk people with features of the metabolic syndrome. Indeed, results of posthoc analyses from the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) and the Bezafibrate Infarction Prevention (BIP) study indicated that treatment with fibrates is beneficial in individuals with diabetes and the metabolic syndrome.180 However, results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study were not as favorable as expected.181,182 The current recommendations for fibrates in the management of dyslipidemia in the metabolic syndrome are the topic of a separate review in this series.180
Niacin (nicotinic acid) lowers VLDL, LDL, and sdLDL and raises HDL cholesterol levels, and thus has an overall beneficial effect on the lipoprotein profile.183 This effect results from inhibition of lipolysis in adipose tissue via G protein–coupled receptors, leading to a reduction of plasma NEFA183,184 and thus limiting the substrate for VLDL secretion. Clinical trials suggest that niacin is a powerful strategy for raising HDL cholesterol.185,186 However, higher doses of niacin (>1.5 g/d) may worsen glycemic control in individuals with type 2 diabetes, and recommendations are to use lower doses and combine with statins.187
Diabetic dyslipoproteinemia is exacerbated by hepatic overproduction of large triglyceride-rich VLDL1, but neither statins nor fibrates reduce the flux of NEFA to the liver or reduce liver fat. Interestingly, the PPAR agonist pioglitazone has been reported to reduce plasma triglyceride levels by increasing VLDL-triglyceride clearance rate with no effect on hepatic secretion of VLDL apoB.188 The effect on clearance rate can be explained by an increase of LPL mass and a reduced apoCIII production in response to pioglitazone.188 Recently, PPAR
agonists have been reported to markedly improve dyslipidemia and also reduce liver fat in obese men.189 Potential future targets include several transcription factors (eg, Foxa2 and Pgc-1b),87,88 key regulatory enzymes in hepatic lipid metabolism (eg, PKC-, DGAT2 and SCD1), lipid intermediates that interfere with insulin signaling,114 and the hypothalamic glucose-sensing mechanisms that regulate liver VLDL-triglyceride production.97,98 Novel targets also include the cannabinoid type 1 (CB1) receptor in the liver: the CB1 receptor antagonist rimonabant has been reported to suppress lipogenesis, lower plasma triglycerides, and raise HDL cholesterol.190
|
Conclusion |
|---|
|
TopAbstractIntroductionFormation and Metabolism of...Dyslipidemia in Insulin...Regulators of VLDL AssemblyWhich Factors Predict...Does Liver Fat Cause...Sources of Fatty Acids...Lipid Management of DyslipidemiaConclusionReferences |
|---|
Several kinetic studies support the view that production of VLDL1 and VLDL2 can be independently regulated,48,77,80,101 and these lipoproteins have different effects on metabolism.191 Overproduction of VLDL1 alters the composition of HDL, which ultimately leads to an increased catabolism of these particles,62 and is closely associated with formation of sdLDL.7 Thus, it is important to realize that VLDL is not a homogenous pool of lipoprotein particles. We are beginning to understand the molecular mechanism(s) involved in the inability of insulin to suppress VLDL1 production in the metabolic syndrome. Hopefully, clarification of these molecular mechanisms will be translated into targeted treatment for dyslipidemia, which is of key importance given the high risk for CVD in patients with the metabolic syndrome.
|
Acknowledgments |
|---|
The authors thank Dr R.S. Perkins for expert editing of the manuscript.
Sources of Funding
This work was supported by the Swedish Research Council, the Swedish Heart-Lung Foundation, the Göran Gustafsson Foundation, the Swedish Foundation for Strategic Research, the Torsten and Ragnar Söderberg Foundation, European Atherosclerosis Society, Sigrid Juselius Foundation, Clinical Research Institute HUCH Ltd, and HEPADIP (EU-project code: ESHM-CT-2005-018734).
Disclosures
M.R.T. has received honoraria from Sanofi-Aventis, Lilly, and Merck Sharp & Dohme, has advisory board appointments for Sanofi-Aventis, Merck Sharp & Dohme, Novartis, and AstraZeneca, and has speakers’ bureau appointments for Merck Sharp & Dohme. J.B. has advisory board appointments for Sanofi-Aventis.
|
Footnotes |
|---|
Original received November 28, 2007; final version accepted April 1, 2008.
|
References |
|---|
|
TopAbstractIntroductionFormation and Metabolism of...Dyslipidemia in Insulin...Regulators of VLDL AssemblyWhich Factors Predict...Does Liver Fat Cause...Sources of Fatty Acids...Lipid Management of DyslipidemiaConclusionReferences |
|---|
1. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003; 46: 733–749.[CrossRef][Medline] [Order article via Infotrieve]
2. Ginsberg HN, Zhang YL, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring). 2006; 14: 41S–49S.[CrossRef]
3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001; 414: 782–787.[CrossRef][Medline] [Order article via Infotrieve]
4. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998; 81: 18B–25B.[CrossRef][Medline] [Order article via Infotrieve]
5. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. Curr Opin Lipidol. 2006; 17: 238–246.[Medline] [Order article via Infotrieve]
6. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab. 2005; 31: 429–439.[CrossRef][Medline] [Order article via Infotrieve]
7. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans. 2003; 31: 1066–1069.[Medline] [Order article via Infotrieve]
8. Olofsson SO, Stillemark-Billton P, Asp L. Intracellular assembly of VLDL: two major steps in separate cell compartments. Trends Cardiovasc Med. 2000; 10: 338–345.[CrossRef][Medline] [Order article via Infotrieve]
9. Olofsson SO, Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med. 2005; 258: 395–410.[CrossRef][Medline] [Order article via Infotrieve]
10. Boren J, Graham L, Wettesten M, Scott J, White A, Olofsson SO. The assembly and secretion of ApoB 100-containing lipoproteins in Hep G2 cells. ApoB 100 is cotranslationally integrated into lipoproteins. J Biol Chem. 1992; 267: 9858–9867.
11. Rustaeus S, Stillemark P, Lindberg K, Gordon D, Olofsson SO. The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipoprotein B-100 very low density lipoprotein in McA-RH7777 cells. J Biol Chem. 1998; 273: 5196–5203.
12. Bostrom K, Boren J, Wettesten M, Sjoberg A, Bondjers G, Wiklund O, Carlsson P, Olofsson SO. Studies on the assembly of apo B-100-containing lipoproteins in HepG2 cells. J Biol Chem. 1988; 263: 4434–4442.
13. Stillemark-Billton P, Beck C, Boren J, Olofsson SO. Relation of the size and intracellular sorting of apoB to the formation of VLDL 1 and VLDL 2. J Lipid Res. 2005; 46: 104–114.
14. Stillemark P, Boren J, Andersson M, Larsson T, Rustaeus S, Karlsson KA, Olofsson SO. The assembly and secretion of apolipoprotein B-48-containing very low density lipoproteins in McA-RH7777 cells. J Biol Chem. 2000; 275: 10506–10513.
15. Asp L, Magnusson B, Rutberg M, Li L, Boren J, Olofsson SO. Role of ADP ribosylation factor 1 in the assembly and secretion of ApoB-100-containing lipoproteins. Arterioscler Thromb Vasc Biol. 2005; 25: 566–570.
16. Gusarova V, Brodsky JL, Fisher EA. Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER. J Biol Chem. 2003; 278: 48051–48058.
17. Gusarova V, Seo J, Sullivan ML, Watkins SC, Brodsky JL, Fisher EA. Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E. J Biol Chem. 2007; 282: 19453–19462.
18. Tran K, Thorne-Tjomsland G, DeLong CJ, Cui Z, Shan J, Burton L, Jamieson JC, Yao Z. Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells. J Biol Chem. 2002; 277: 31187–31200.
19. Yamaguchi J, Gamble MV, Conlon D, Liang JS, Ginsberg HN. The conversion of apoB100 low density lipoprotein/high density lipoprotein particles to apoB100 very low density lipoproteins in response to oleic acid occurs in the endoplasmic reticulum and not in the Golgi in McA RH7777 cells. J Biol Chem. 2003; 278: 42643–42651.
20. Wiggins D, Gibbons GF. The lipolysis/esterification cycle of hepatic triacylglycerol. Its role in the secretion of very-low-density lipoprotein and its response to hormones and sulphonylureas. Biochem J. 1992; 284: 457–462.[Medline] [Order article via Infotrieve]
21. Salter AM, Wiggins D, Sessions VA, Gibbons GF. The intracellular triacylglycerol/fatty acid cycle: a comparison of its activity in hepatocytes which secrete exclusively apolipoprotein (apo) B100 very-low-density lipoprotein (VLDL) and in those which secrete predominantly apoB48 VLDL. Biochem J. 1998; 332: 667–672.[Medline] [Order article via Infotrieve]
22. Gibbons GF, Islam K, Pease RJ. Mobilisation of triacylglycerol stores. Biochim Biophys Acta. 2000; 1483: 37–57.[Medline] [Order article via Infotrieve]
23. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986; 78: 1287–1295.[Medline] [Order article via Infotrieve]
24. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986; 232: 34–47.
25. Phair RD, Hammond MG, Bowden JA, Fried M, Fisher WR, Berman M. Preliminary model for human lipoprotein metabolism in hyperlipoproteinemia. Fed Proc. 1975; 34: 2263–2270.[Medline] [Order article via Infotrieve]
26. Gaw A, Packard CJ, Lindsay GM, Griffin BA, Caslake MJ, Lorimer AR, Shepherd J. Overproduction of small very low density lipoproteins (Sf 20–60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res. 1995; 36: 158–171.[Abstract]
27. Soutar AK, Myant NB, Thompson GR. The metabolism of very low density and intermediate density lipoproteins in patients with familial hypercholesterolaemia. Atherosclerosis. 1982; 43: 217–231.[CrossRef][Medline] [Order article via Infotrieve]
28. James RW, Martin B, Pometta D, Fruchart JC, Duriez P, Puchois P, Farriaux JP, Tacquet A, Demant T, Clegg RJ, et al. Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res. 1989; 30: 159–169.[Abstract]
29. Parhofer KG, Barrett PH. Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies. J Lipid Res. 2006; 47: 1620–1630.
30. Patterson BW, Mittendorfer B, Elias N, Satyanarayana R, Klein S. Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. J Lipid Res. 2002; 43: 223–233.
31. Chan DC, Barrett PH, Watts GF. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol. 2006; 17: 28–36.[Medline] [Order article via Infotrieve]
32. Chan DC, Watts GF, Nguyen MN, Barrett PH. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 Kinetics. Arterioscler Thromb Vasc Biol. 2006; 26: 590–596.
33. Marsh JB, Welty FK, Lichtenstein AH, Lamon-Fava S, Schaefer EJ. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis. 2002; 162: 227–244.[CrossRef][Medline] [Order article via Infotrieve]
34. Zech LA, Grundy SM, Steinberg D, Berman M. Kinetic model for production and metabolism of very low density lipoprotein triglycerides. Evidence for a slow production pathway and results for normolipidemic subjects. J Clin Invest. 1979; 63: 1262–1273.[Medline] [Order article via Infotrieve]
35. Magkos F, Sidossis LS. Measuring very low density lipoprotein-triglyceride kinetics in man in vivo: how different the various methods really are. Curr Opin Clin Nutr Metab Care. 2004; 7: 547–555.[CrossRef][Medline] [Order article via Infotrieve]
36. Adiels M, Packard C, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Taskinen MR, Boren J. A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res. 2005; 46: 58–67.
37. Barrett PH, Baker N, Nestel PJ. Model development to describe the heterogeneous kinetics of apolipoprotein B and triglyceride in hypertriglyceridemic subjects. J Lipid Res. 1991; 32: 743–762.[Abstract]
38. Melish J, Le NA, Ginsberg H, Steinberg D, Brown WV. Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins. Am J Physiol Endocrinol Metab. 1980; 239: E354–E362.
39. Steiner G, Reardon MF. A new model of human VLDL metabolism based on simultaneous studies of its APOB and triglyceride. Metabolism. 1983; 32: 342–347.[CrossRef][Medline] [Order article via Infotrieve]
40. Beltz WF, Kesaniemi YA, Miller NH, Fisher WR, Grundy SM, Zech LA. Studies on the metabolism of apolipoprotein B in hypertriglyceridemic subjects using simultaneous administration of tritiated leucine and radioiodinated very low density lipoprotein. J Lipid Res. 1990; 31: 361–374.[Abstract]
41. Desroches S, Paradis ME, Perusse M, Archer WR, Bergeron J, Couture P, Bergeron N, Lamarche B. Apolipoprotein A-I, A-II, and VLDL-B-100 metabolism in men: comparison of a low-fat diet and a high-monounsaturated fatty acid diet. J Lipid Res. 2004; 45: 2331–2338.
42. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes. 1982; 31: 217–225.[Abstract]
43. Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest. 2000; 30: 685–694.[CrossRef][Medline] [Order article via Infotrieve]
44. Ouguerram K, Magot T, Zair Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther. 2003; 306: 332–337.
45. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Naoumova R, Slavin BM, Thompson GR, Sonksen PH. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia. 1995; 38: 959–967.[Medline] [Order article via Infotrieve]
46. Adiels M, Boren J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Packard C, Taskinen MR. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2005; 25: 1697–1703.
47. Taskinen MR, Packard CJ, Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes. 1990; 39: 1017–1027.[Abstract]
48. Gill JM, Brown JC, Bedford D, Wright DM, Cooney J, Hughes DA, Packard CJ, Caslake MJ. Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis. 2004; 176: 49–56.[CrossRef][Medline] [Order article via Infotrieve]
49. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, Boren J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006; 49: 755–765.[CrossRef][Medline] [Order article via Infotrieve]
50. Riches FM, Watts GF, Naoumova RP, Kelly JM, Croft KD, Thompson GR. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord. 1998; 22: 414–423.[CrossRef][Medline] [Order article via Infotrieve]
51. Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism. 2002; 51: 1041–1046.[CrossRef][Medline] [Order article via Infotrieve]
52. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 2003; 52: 803–811.
53. Pont F, Duvillard L, Florentin E, Gambert P, Verges B. Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity. Arterioscler Thromb Vasc Biol. 2002; 22: 1726–1732.
54. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Plasma low density lipoprotein transport kinetics in noninsulin-dependent diabetes mellitus. J Clin Invest. 1983; 71: 655–667.[CrossRef][Medline] [Order article via Infotrieve]
55. Georgieva AM, van Greevenbroek MM, Krauss RM, Brouwers MC, Vermeulen VM, Robertus-Teunissen MG, van der Kallen CJ, de Bruin TW. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler Thromb Vasc Biol. 2004; 24: 744–749.
56. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb. 1992; 12: 1496–1502.
57. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990; 82: 495–506.
58. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997; 95: 69–75.
59. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc. 1996; 276: 875–881.
60. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003; 107: 1733–1737.
61. Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab. 2003; 88: 4525–4532.
62. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003; 36: 421–429.[CrossRef][Medline] [Order article via Infotrieve]
63. Cohn JS, Johnson EJ, Millar JS, Cohn SD, Milne RW, Marcel YL, Russell RM, Schaefer EJ. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res. 1993; 34: 2033–2040.[Abstract]
64. Karpe F, Bell M, Bjorkegren J, Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol. 1995; 15: 199–207.
65. Schneeman BO, Kotite L, Todd KM, Havel RJ. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci U S A. 1993; 90: 2069–2073.
66. Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev. 2002; 18: 484–490.[CrossRef][Medline] [Order article via Infotrieve]
67. Lichtenstein AH, Hachey DL, Millar JS, Jenner JL, Booth L, Ordovas J, Schaefer EJ. Measurement of human apolipoprotein B-48 and B-100 kinetics in triglyceride-rich lipoproteins using [5,5,5–2H3]leucine. J Lipid Res. 1992; 33: 907–914.[Abstract]
68. Welty FK, Lichtenstein AH, Barrett PHR, Dolnikowski GG, Schaefer EJ. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol. 1999; 19: 2966–2974.
69. Brunzell JD, Hazzard WR, Porte D Jr, Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest. 1973; 52: 1578–1585.[Medline] [Order article via Infotrieve]
70. Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest. 1993; 92: 160–168.[Medline] [Order article via Infotrieve]
71. Kwiterovich PO, Jr. HyperapoB: a pleiotropic phenotype characterized by dense low-density lipoproteins and associated with coronary artery disease. Clin Chem. 1988; 34: B71–77.[Medline] [Order article via Infotrieve]
72. Hunt SC, Wu LL, Hopkins PN, Stults BM, Kuida H, Ramirez ME, Lalouel JM, Williams RR. Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension. Arteriosclerosis. 1989; 9: 335–344.
73. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 1993; 92: 141–146.[Medline] [Order article via Infotrieve]
74. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993; 44: 121–131.[CrossRef][Medline] [Order article via Infotrieve]
75. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995; 95: 158–166.[Medline] [Order article via Infotrieve]
76. Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol. 1997; 8: 146–153.[Medline] [Order article via Infotrieve]
77. Malmstrom R, Packard CJ, Watson TD, Rannikko S, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol. 1997; 17: 1454–1464.
78. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes. 1998; 47: 779–787.[Abstract]
79. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes. 1993; 42: 833–842.[Abstract]
80. Adiels M, Westerbacka J, Soro-Paavonen A, Häkkinen A, Vehkavaara S, MJCaslake, Packard C, Olofsson S, Yki-Järvinen H, Taskinen M, Borén J. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia. In Press.
81. Phung TL, Roncone A, Jensen KL, Sparks CE, Sparks JD. Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J Biol Chem. 1997; 272: 30693–30702.
82. Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta. 1994; 1215: 9–32.[Medline] [Order article via Infotrieve]
83. Sparks JD, Phung TL, Bolognino M, Sparks CE. Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Biochem J. 1996; 313 (Pt 2): 567–574.[Medline] [Order article via Infotrieve]
84. Au CS, Wagner A, Chong T, Qiu W, Sparks JD, Adeli K. Insulin regulates hepatic apolipoprotein B production independent of the mass or activity of Akt1/PKBalpha. Metabolism. 2004; 53: 228–235.[CrossRef][Medline] [Order article via Infotrieve]
85. Allister EM, Borradaile NM, Edwards JY, Huff MW. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes. 2005; 54: 1676–1683.
86. Wolfrum C, Besser D, Luca E, Stoffel M. Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc Natl Acad Sci U S A. 2003; 100: 11624–11629.
87. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature. 2004; 432: 1027–1032.[CrossRef][Medline] [Order article via Infotrieve]
88. Wolfrum C, Stoffel M. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab. 2006; 3: 99–110.[CrossRef][Medline] [Order article via Infotrieve]
89. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005; 54: 2460–2470.
90. Maragoudakis ME, Hankin H. On the mode of action of lipid-lowering agents. V. Kinetics of the inhibition in vitro of rat acetyl coenzyme A carboxylase. J Biol Chem. 1971; 246: 348–358.
91. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998; 98: 2088–2093.
92. Linden D, Lindberg K, Oscarsson J, Claesson C, Asp L, Li L, Gustafsson M, Boren J, Olofsson SO. Influence of peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48. J Biol Chem. 2002; 277: 23044–23053.
93. Watts GF, Ji J, Chan DC, Ooi EM, Johnson AG, Rye KA, Barrett PH. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clin Sci (Lond). 2006; 111: 193–199.[Medline] [Order article via Infotrieve]
94. Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagne C, Couture P. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism. 2008; 57: 246–254.[CrossRef][Medline] [Order article via Infotrieve]
95. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol. 1983; 25: 57–63.[CrossRef][Medline] [Order article via Infotrieve]
96. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart J-C, Dallongeville J, Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest. 1995; 95: 705–712.[Medline] [Order article via Infotrieve]
97. Lam TK, Gutierrez-Juarez R, Pocai A, Bhanot S, Tso P, Schwartz GJ, Rossetti L. Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. Nat Med. 2007; 13: 171–180.[CrossRef][Medline] [Order article via Infotrieve]
98. Pocai A, Obici S, Schwartz GJ, Rossetti L. A brain-liver circuit regulates glucose homeostasis. Cell Metab. 2005; 1: 53–61.[CrossRef][Medline] [Order article via Infotrieve]
99. Mittendorfer B, Patterson BW, Klein S, Sidossis LS. VLDL-triglyceride kinetics during hyperglycemia-hyperinsulinemia: effects of sex and obesity. Am J Physiol Endocrinol Metab. 2003; 284: E708–E715.
100. Fielding BA, Reid G, Grady M, Humphreys SM, Evans K, Frayn KN. Ethanol with a mixed meal increases postprandial triacylglycerol but decreases postprandial non-esterified fatty acid concentrations. Br J Nutr. 2000; 83: 597–604.[Medline] [Order article via Infotrieve]
101. Prinsen BH, Romijn JA, Bisschop PH, de Barse MM, Barrett PH, Ackermans M, Berger R, Rabelink TJ, de Sain-van der Velden MG. Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans. J Lipid Res. 2003; 44: 1341–1348.
102. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003; 37: 1202–1219.[CrossRef][Medline] [Order article via Infotrieve]
103. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG, Zalunardo B, Lirussi F, Alessandri C, Violi F. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2005; 90: 1578–1582.
104. Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep. 2002; 2: 210–215.[Medline] [Order article via Infotrieve]
105. Youssef W, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis. 2002; 13: 17–30.[Medline] [Order article via Infotrieve]
106. Li Z, Clark J, Diehl AM. The liver in obesity and type 2 diabetes mellitus. Clin Liver Dis. 2002; 6: 867–877.[CrossRef][Medline] [Order article via Infotrieve]
107. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50: 1844–1850.
108. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37: 917–923.[CrossRef][Medline] [Order article via Infotrieve]
109. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005; 42: 987–1000.[CrossRef][Medline] [Order article via Infotrieve]
110. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005; 54: 3541–3546.
111. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005; 11: 191–198.[CrossRef][Medline] [Order article via Infotrieve]
112. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002; 35: 373–379.[CrossRef][Medline] [Order article via Infotrieve]
113. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107: 450–455.[CrossRef][Medline] [Order article via Infotrieve]
114. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA. Lipid mediators of insulin resistance. Nutr Rev. 2007; 65: S39–46.[Medline] [Order article via Infotrieve]
115. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002; 277: 50230–50236.
116. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N, Neschen S, White MF, Bilz S, Sono S, Pypaert M, Shulman GI. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest. 2005; 115: 3587–3593.[CrossRef][Medline] [Order article via Infotrieve]
117. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006; 55 Suppl 2: S9–S15.
118. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Aleman JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008; 7: 125–134.[CrossRef][Medline] [Order article via Infotrieve]
119. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007; 87: 507–520.
120. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004; 279: 32345–32353.
121. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest. 2007; 117: 739–745.[CrossRef][Medline] [Order article via Infotrieve]
122. Considine RV, Nyce MR, Allen LE, Morales LM, Triester S, Serrano J, Colberg J, Lanza-Jacoby S, Caro JF. Protein kinase C is increased in the liver of humans and rats with non-insulin-dependent diabetes mellitus: an alteration not due to hyperglycemia. J Clin Invest. 1995; 95: 2938–2944.[Medline] [Order article via Infotrieve]
123. Nagle CA, An J, Shiota M, Torres TP, Cline GW, Liu ZX, Wang S, Catlin RL, Shulman GI, Newgard CB, Coleman RA. Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance. J Biol Chem. 2007; 282: 14807–14815.
124. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A. 2001; 98: 7522–7527.
125. An J, Muoio DM, Shiota M, Fujimoto Y, Cline GW, Shulman GI, Koves TR, Stevens R, Millington D, Newgard CB. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med. 2004; 10: 268–274.[CrossRef][Medline] [Order article via Infotrieve]
126. Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, Samuel VT, Neschen S, Zhang D, Wang A, Zhang XM, Kahn M, Cline GW, Pandey SK, Geisler JG, Bhanot S, Monia BP, Shulman GI. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem. 2007; 282: 22678–22688.
127. Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, Song XZ, Kelly S, Chen S, McKay R, Monia BP, Bhanot S. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology. 2005; 42: 362–371.[CrossRef][Medline] [Order article via Infotrieve]
128. Monetti M, Levin MC, Watt MJ, Sajan MP, Marmor S, Hubbard BK, Stevens RD, Bain JR, Newgard CB, Farese RV, Sr., Hevener AL, Farese RV Jr. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 2007; 6: 69–78.[CrossRef][Medline] [Order article via Infotrieve]
129. Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, Adinolfi LE, Ruggiero G, Carulli N, Loria P. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol. 2006; 44: 190–196.[CrossRef][Medline] [Order article via Infotrieve]
130. Martin S, Parton RG. Lipid droplets: a unified view of a dynamic organelle. Nat Rev Mol Cell Biol. 2006; 7: 373–378.[CrossRef][Medline] [Order article via Infotrieve]
131. Holm C, Osterlund T, Laurell H, Contreras JA. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Annu Rev Nutr. 2000; 20: 365–393.[CrossRef][Medline] [Order article via Infotrieve]
132. Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R, Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A, Zechner R. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science. 2004; 306: 1383–1386.
133. Villena JA, Roy S, Sarkadi-Nagy E, Kim KH, Sul HS. Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis. J Biol Chem. 2004; 279: 47066–47075.
134. Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem. 2004; 279: 48968–48975.
135. Londos C, Brasaemle DL, Schultz CJ, Adler-Wailes DC, Levin DM, Kimmel AR, Rondinone CM. On the control of lipolysis in adipocytes. Ann N Y Acad Sci. 1999; 892: 155–168.[CrossRef][Medline] [Order article via Infotrieve]
136. Londos C, Brasaemle DL, Schultz CJ, Segrest JP, Kimmel AR. Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Semin Cell Dev Biol. 1999; 10: 51–58.[CrossRef][Medline] [Order article via Infotrieve]
137. Londos C, Sztalryd C, Tansey JT, Kimmel AR. Role of PAT proteins in lipid metabolism. Biochimie. 2005; 87: 45–49.[Medline] [Order article via Infotrieve]
138. Bell M, Fried SK, Londos C, Sztalryd C. ADRP and Tip-47 down-regulation results in abnormal lipid droplet morphology, lipid metabolism and insulin-stimulated Akt phosphorylation in cultured liver cells. Diabetes. 2006; 55: A326–A326.[CrossRef]
139. Dvorak AM, Weller PF, Harvey VS, Morgan ES, Dvorak HF. Ultrastructural localization of prostaglandin endoperoxide synthase (cyclooxygenase) to isolated, purified fractions of guinea pig peritoneal macrophage and line 10 hepatocarcinoma cell lipid bodies. Int Arch Allergy Immunol. 1993; 101: 136–142.[Medline] [Order article via Infotrieve]
140. Bozza PT, Yu W, Penrose JF, Morgan ES, Dvorak AM, Weller PF. Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J Exp Med. 1997; 186: 909–920.
141. Yu W, Bozza PT, Tzizik DM, Gray JP, Cassara J, Dvorak AM, Weller PF. Co-compartmentalization of MAP kinases and cytosolic phospholipase A2 at cytoplasmic arachidonate-rich lipid bodies. Am J Pathol. 1998; 152: 759–769.[Abstract]
142. Yu W, Cassara J, Weller PF. Phosphatidylinositide 3-kinase localizes to cytoplasmic lipid bodies in human polymorphonuclear leukocytes and other myeloid-derived cells. Blood. 2000; 95: 1078–1085.
143. Umlauf E, Csaszar E, Moertelmaier M, Schuetz GJ, Parton RG, Prohaska R. Association of stomatin with lipid bodies. J Biol Chem. 2004; 279: 23699–23709.
144. Liu P, Ying Y, Zhao Y, Mundy DI, Zhu M, Anderson RG. Chinese hamster ovary K2 cell lipid droplets appear to be metabolic organelles involved in membrane traffic. J Biol Chem. 2004; 279: 3787–3792.
145. Brasaemle DL, Dolios G, Shapiro L, Wang R. Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3–L1 adipocytes. J Biol Chem. 2004; 279: 46835–46842.
146. Wan HC, Melo RC, Jin Z, Dvorak AM, Weller PF. Roles and origins of leukocyte lipid bodies: proteomic and ultrastructural studies. Faseb J. 2007; 21: 167–178.
147. Bozza PT, Melo RC, Bandeira-Melo C. Leukocyte lipid bodies regulation and function: contribution to allergy and host defense. Pharmacol Ther. 2007; 113: 30–49.[CrossRef][Medline] [Order article via Infotrieve]
148. Bostrom P, Andersson L, Rutberg M, Perman J, Lidberg U, Johansson BR, Fernandez-Rodriguez J, Ericson J, Nilsson T, Boren J, Olofsson SO. SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity. Nat Cell Biol. 2007; 9: 1286–1293.[CrossRef][Medline] [Order article via Infotrieve]
149. Parks EJ, Hellerstein MK. Thematic review series: patient-oriented research. Recent advances in liver triacylglycerol and fatty acid metabolism using stable isotope labeling techniques. J Lipid Res. 2006; 47: 1651–1660.
150. Barrows BR, Parks EJ. Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab. 2006; 91: 1446–1452.
151. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005; 115: 1343–1351.[CrossRef][Medline] [Order article via Infotrieve]
152. Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest. 2005; 115: 1139–1142.[CrossRef][Medline] [Order article via Infotrieve]
153. Farquhar JW, Gross RC, Wagner RM, Reaven GM. Validation of an incompletely coupled two-compartment nonrecycling catenary model for turnover of liver and plasma triglyceride in man. J Lipid Res. 1965; 6: 119–134.[Abstract]
154. Parks EJ, Krauss RM, Christiansen MP, Neese RA, Hellerstein MK. Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J Clin Invest. 1999; 104: 1087–1096.[Medline] [Order article via Infotrieve]
155. Havel RJ. Conversion of plasma free fatty acids into triglycerides of plasma lipoprotein fractions in man. Metabolism. 1961; 10: 1031–1034.[Medline] [Order article via Infotrieve]
156. Goldberg IJ, Ginsberg HN. Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology. 2006; 130: 1343–1346.[CrossRef][Medline] [Order article via Infotrieve]
157. Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, Hisatomi A, Ozaki I, Yamamoto K, Kitajima Y, Kawaguchi Y, Kuroki S, Ono N. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol. 2006; 41: 462–469.[CrossRef][Medline] [Order article via Infotrieve]
158. Hodson L, Bickerton AS, McQuaid SE, Roberts R, Karpe F, Frayn KN, Fielding BA. The contribution of splanchnic fat to VLDL triglyceride is greater in insulin-resistant than insulin-sensitive men and women: studies in the postprandial state. Diabetes. 2007; 56: 2433–2441.[CrossRef][Medline] [Order article via Infotrieve]
159. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest. 2004; 113: 1582–1588.[CrossRef][Medline] [Order article via Infotrieve]
160. Timlin MT, Parks EJ. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am J Clin Nutr. 2005; 81: 35–42.
161. Hudgins LC, Hellerstein M, Seidman C, Neese R, Diakun J, Hirsch J. Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J Clin Invest. 1996; 97: 2081–2091.[Medline] [Order article via Infotrieve]
162. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, Befroy D, Zemany L, Kahn BB, Papademetris X, Rothman DL, Shulman GI. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A. 2007; 104: 12587–12594.
163. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004; 114: 147–152.[CrossRef][Medline] [Order article via Infotrieve]
164. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 1999; 274: 30028–30032.
165. Koo SH, Dutcher AK, Towle HC. Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme genes in liver. J Biol Chem. 2001; 276: 9437–9445.
166. Edvardsson U, Bergstrom M, Alexandersson M, Bamberg K, Ljung B, Dahllof B. Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res. 1999; 40: 1177–1184.
167. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, Reitman ML. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest. 2000; 106: 1221–1228.[Medline] [Order article via Infotrieve]
168. Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Siren J, Hamsten A, Fisher RM, Yki-Jarvinen H. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes. 2007; 56: 2759–2765.
169. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Faga E, Silli B, Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003; 37: 909–916.[CrossRef][Medline] [Order article via Infotrieve]
170. Boberg J, Carlson LA, Freyschuss U. Determination of splanchnic secretion rate of plasma triglycerides and of total and splanchnic turnover of plasma free fatty acids in man. Eur J Clin Invest. 1972; 2: 123–132.[Medline] [Order article via Infotrieve]
171. Vedala A, Wang W, Neese RA, Christiansen MP, Hellerstein MK. Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. J Lipid Res. 2006; 47: 2562–2574.
172. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364: 685–696.[CrossRef][Medline] [Order article via Infotrieve]
173. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361: 2005–2016.[CrossRef][Medline] [Order article via Infotrieve]
174. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267–1278.[CrossRef][Medline] [Order article via Infotrieve]
175. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006; 29: 1220–1226.
176. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006; 368: 919–928.[CrossRef][Medline] [Order article via Infotrieve]
177. Pyorala K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjekshus J. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 2004; 27: 1735–1740.
178. Ginsberg HN. REVIEW. Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2006; 91: 383–392.
179. Dane-Stewart CA, Watts GF, Pal S, Chan D, Thompson P, Hung J, Mamo JC. Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism. 2003; 52: 1279–1286.[CrossRef][Medline] [Order article via Infotrieve]
180. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol. 2008; 28: 39–46.
181. Verges B. Role for fibrate therapy in diabetes: evidence before FIELD. Curr Opin Lipidol. 2005; 16: 648–651.[Medline] [Order article via Infotrieve]
182. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366: 1849–1861.[CrossRef][Medline] [Order article via Infotrieve]
183. Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep. 2000; 2: 36–46.[Medline] [Order article via Infotrieve]
184. Carlson LA, Havel RJ, Ekelund LG, Holmgren A. Effect of nicotinic acid on the turnover rate and oxidation of the free fatty acids of plasma in man during exercise. Metabolism. 1963; 12: 837–845.[Medline] [Order article via Infotrieve]
185. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol. 2007; 18: 415–420.[CrossRef][Medline] [Order article via Infotrieve]
186. Superko HR. The failure of LDL cholesterol reduction and the importance of reverse cholesterol transport. The role of nicotinic acid. Br J Cardiol. 2006; 13: 131–136.
187. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002; 162: 1568–1576.
188. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest. 2005; 115: 1323–1332.[CrossRef][Medline] [Order article via Infotrieve]
189. Riserus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008; 57: 332–339.
190. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353: 2121–2134.
191. Millar JS, Packard CJ. Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies. Curr Opin Lipidol. 1998; 9: 197–202.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  J. L. Estall, M. Kahn, M. P. Cooper, f. M. Fisher, M. K. Wu, D. Laznik, L. Qu, D. E. Cohen, G. I. Shulman, and B. M. Spiegelman Sensitivity of Lipid Metabolism and Insulin Signaling to Genetic Alterations in Hepatic Peroxisome Proliferator-Activated Receptor-{gamma} Coactivator-1{alpha} Expression Diabetes, July 1, 2009; 58(7): 1499 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tsai, R. Zhang, W. Qiu, Q. Su, M. Naples, and K. Adeli Inflammatory NF-{kappa}B activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production Am J Physiol Gastrointest Liver Physiol, June 1, 2009; 296(6): G1287 - G1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Taskinen ADAGIO-Lipids Gives Promises but Faces the Setbacks Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 339 - 340. [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Chan, P. H. R. Barrett, E. M. M. Ooi, J. Ji, D. T. Chan, and G. F. Watts Very Low Density Lipoprotein Metabolism and Plasma Adiponectin as Predictors of High-Density Lipoprotein Apolipoprotein A-I Kinetics in Obese and Nonobese Men J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 989 - 997. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||